JP2012532899A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532899A5
JP2012532899A5 JP2012519900A JP2012519900A JP2012532899A5 JP 2012532899 A5 JP2012532899 A5 JP 2012532899A5 JP 2012519900 A JP2012519900 A JP 2012519900A JP 2012519900 A JP2012519900 A JP 2012519900A JP 2012532899 A5 JP2012532899 A5 JP 2012532899A5
Authority
JP
Japan
Prior art keywords
het
conr
hal
atoms
absent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012519900A
Other languages
English (en)
Japanese (ja)
Other versions
JP5681182B2 (ja
JP2012532899A (ja
Filing date
Publication date
Priority claimed from DE102009033208A external-priority patent/DE102009033208A1/de
Application filed filed Critical
Publication of JP2012532899A publication Critical patent/JP2012532899A/ja
Publication of JP2012532899A5 publication Critical patent/JP2012532899A5/ja
Application granted granted Critical
Publication of JP5681182B2 publication Critical patent/JP5681182B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012519900A 2009-07-15 2010-06-17 腫瘍および炎症性疾患の処置のためのアミノピリジン誘導体 Expired - Fee Related JP5681182B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102009033208.1 2009-07-15
DE102009033208A DE102009033208A1 (de) 2009-07-15 2009-07-15 Aminopyridinderivate
PCT/EP2010/003659 WO2011006567A1 (de) 2009-07-15 2010-06-17 Aminopyridinderivate zur behandlung von tumoren und entzündungskrankheiten

Publications (3)

Publication Number Publication Date
JP2012532899A JP2012532899A (ja) 2012-12-20
JP2012532899A5 true JP2012532899A5 (enExample) 2013-08-29
JP5681182B2 JP5681182B2 (ja) 2015-03-04

Family

ID=42665826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012519900A Expired - Fee Related JP5681182B2 (ja) 2009-07-15 2010-06-17 腫瘍および炎症性疾患の処置のためのアミノピリジン誘導体

Country Status (11)

Country Link
US (1) US8648201B2 (enExample)
EP (1) EP2454253B1 (enExample)
JP (1) JP5681182B2 (enExample)
CN (1) CN102471317B (enExample)
AR (1) AR077567A1 (enExample)
AU (1) AU2010272920B2 (enExample)
CA (1) CA2768169C (enExample)
DE (1) DE102009033208A1 (enExample)
ES (1) ES2534095T3 (enExample)
IL (1) IL217467A (enExample)
WO (1) WO2011006567A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104030987B (zh) * 2009-04-02 2017-04-12 默克雪兰诺有限公司 二氢乳清酸脱氢酶抑制剂
WO2011058139A1 (en) * 2009-11-12 2011-05-19 Selvita Sp. Z O. O. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
EP2509975B1 (en) * 2009-12-04 2014-04-23 Boehringer Ingelheim International GmbH Benzimidazole inhibitors of leukotriene production
JP5997709B2 (ja) * 2011-03-04 2016-09-28 レクシコン ファーマシューティカルズ インコーポレイテッド Mst1キナーゼ阻害剤及びその使用方法
US20140315881A1 (en) * 2011-07-29 2014-10-23 Tempero Pharmaceuticals, Inc. Compounds and methods
EP2802577B1 (en) * 2012-01-13 2017-03-01 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
CA2878621C (en) * 2012-07-10 2020-09-15 Ares Trading S.A. Pyrimidine pyrazolyl derivatives
WO2014058685A1 (en) * 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
US9586948B2 (en) 2012-10-08 2017-03-07 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
EP3019171B1 (en) 2013-07-11 2018-09-05 Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
EP3107901B1 (en) 2014-02-19 2020-04-01 Piramal Enterprises Limited Compounds for use as gpr120 agonists
US10273230B2 (en) 2014-07-25 2019-04-30 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
CA2960757C (en) * 2014-09-11 2022-09-06 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
EP3325100A4 (en) 2015-07-17 2019-02-20 Memorial Sloan-Kettering Cancer Center COMBINATION THERAPY WITH PDK1 AND PI3K INHIBITORS
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
TWI721483B (zh) 2018-07-13 2021-03-11 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
CN112457308B (zh) * 2019-09-09 2024-01-02 上海长森药业有限公司 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用
US11767321B2 (en) 2020-10-05 2023-09-26 Enliven Inc. 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases
JP2025507902A (ja) * 2022-03-02 2025-03-21 杭州百誠医薬科技股▲ふん▼有限公司 ヒスタミンh3受容体阻害剤及びその医薬における使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US6818419B2 (en) 2000-01-13 2004-11-16 Tularik Inc. IRAK-4: compositions and methods of use
WO2003030902A1 (en) 2001-10-09 2003-04-17 Tularik Inc. Imidazole derivates as anti-inflammatory agents
ES2437391T3 (es) * 2002-02-06 2014-01-10 Vertex Pharmaceuticals, Inc. Compuestos de heteroarilo útiles como inhibidores de GSK-3
CA2502429A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
WO2004069160A2 (en) 2003-01-28 2004-08-19 Smithkline Beecham Corporation Chemical compounds
JP2008510792A (ja) 2004-08-26 2008-04-10 ファイザー・インク タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物
NZ571933A (en) 2006-03-22 2011-06-30 Vertex Pharma C-Met protein kinase inhibitors for the treatment of proliferative disorders
EP2173445B1 (en) 2007-06-29 2011-10-12 Vekoma Rides Engineering B.V. Amusement device seat assembly
WO2009024825A1 (en) * 2007-08-21 2009-02-26 Astrazeneca Ab 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors
JP2011500778A (ja) 2007-10-25 2011-01-06 アストラゼネカ・アクチエボラーグ ピリジン及びピラジン誘導体−083
WO2009099982A1 (en) 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
KR100979439B1 (ko) 2008-04-10 2010-09-02 한국화학연구원 신규 피라졸 및 벤즈옥사졸 치환된 피리딘 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 이상세포 성장 질환의 예방 및치료용 약학적 조성물

Similar Documents

Publication Publication Date Title
JP2012532899A5 (enExample)
JP2012506389A5 (enExample)
JP2014520767A5 (enExample)
JP2014508811A5 (enExample)
JP2011530545A5 (enExample)
JP2010529051A5 (enExample)
JP2012092103A5 (enExample)
JP2010532768A5 (enExample)
JP2014508753A5 (enExample)
JP2012111953A5 (enExample)
JP2012532901A5 (enExample)
JP2010526025A5 (enExample)
JP2015536947A5 (enExample)
JP2010095546A5 (enExample)
JP2009529540A5 (enExample)
HRP20161103T1 (hr) Kemijski spojevi
JP2013542218A5 (enExample)
RU2018116351A (ru) Пиримидиновое соединение
JP2012506896A5 (enExample)
JP2009501198A5 (enExample)
JP2018533593A5 (enExample)
JP2010510177A5 (enExample)
JP2015522650A5 (enExample)
JP2013521295A5 (enExample)
AR093532A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias